Phase II CONCUR aHUS Trial
In the fourth quarter of 2017, we opened our first site for a 180-day, open-label, Phase II, single-arm study to evaluate the safety and efficacy of Coversin in newly diagnosed or relapsed adult aHUS patients.
We plan to recruit up to ten patients in study sites in Europe. Upon completion of the trial, patients will have the option of remaining on Coversin and being entered into our long-term safety and efficacy CONSERVE study.
The primary endpoint of the trial is normal platelet count at day 180.
This Phase II clinical trial is currently recruiting.